Original Article

You have full text access to this OnlineOpen article

Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in Cancer 2006;106(11):2530] †

  1. Tawee Tanvetyanon M.D.1,2,‡,*

Article first published online: 13 DEC 2004

DOI: 10.1002/cncr.20766

Issue

Cancer

Cancer

Volume 103, Issue 2, pages 237–241, 15 January 2005

Additional Information

How to Cite

Tanvetyanon, T. (2005), Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in Cancer 2006;106(11):2530] . Cancer, 103: 237–241. doi: 10.1002/cncr.20766

Author Information

  1. 1

    Division of Hematology and Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois

  2. 2

    Medical Service, Edward Hines Jr. Veterans Administration Hospital, Hines, Illinois

  1. ‡

    Fax: (708) 327-3326

*Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago Medical Center, 2160 South First Avenue, Maywood, IL 60153

  1. †

    The opinions expressed herein do not necessarily reflect the views of the U.S. Department of Veterans Affairs.

Publication History

  1. Issue published online: 5 JAN 2005
  2. Article first published online: 13 DEC 2004
  3. Manuscript Revised: 24 SEP 2004
  4. Manuscript Accepted: 24 SEP 2004
  5. Manuscript Received: 28 JAN 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (101K)

REFERENCES

  • 1
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 1781–1788.
  • 2
    Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997; 79: 235–246.
  • 3
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a World Health Organization study group. WHO Tech Rep Ser. 1994; 843: 1–129.
  • 4
    Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997; 79: 545–550.
    Direct Link:
  • 5
    Melton LJ III, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. Fracture risk following bilateral orchiectomy. J Urol. 2003; 169: 1747–1750.
  • 6
    Morote J, Martinez E, Trilla E, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol. 2003; 44: 661–665.
  • 7
    Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003; 92: 690–694.
    Direct Link:
  • 8
    Bonar SK, Tinetti ME, Speechley M, Cooney LM. Factors associated with short- versus long-term skilled nursing facility placement among community-living hip fracture patients. J Am Geriatr Soc. 1990; 38: 1139–1144.
  • 9
    Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997; 12: 24–35.
    Direct Link:
  • 10
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353: 878–882.
  • 11
    Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993; 341: 72–75.
  • 12
    Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345: 948–955.
  • 13
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169: 2008–2012.
  • 14
    Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343: 604–610.
  • 15
    Peacock M, Liu G, Carey M, et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab. 2000; 85: 3011–3019.
  • 16
    Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum. 2002; 46: 3136–3142.
    Direct Link:
  • 17
    Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002; 162: 2217–2222.
  • 18
    Gallagher TC, Geling O, Comite F. Missed opportunities for prevention of osteoporotic fracture. Arch Intern Med. 2002; 162: 450–456.
  • 19
    Lee E, Zuckerman IH, Weiss SR. Patterns of pharmacotherapy and counseling for osteoporosis management in visits to US ambulatory care physicians by women. Arch Intern Med. 2002; 162: 2362–2366.
  • 20
    Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med. 2001; 161: 1322–1327.
  • 21
    Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137: 529–541.
  • 22
    Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974; 131: 1121–1123.
  • 23
    American Gastroenterological Association. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124: 791–794.
  • 24
    U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002; 137: 526–528.
  • 25
    American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996; 39: 1791–1801.
    Direct Link:
  • 26
    Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458–1468.
  • 27
    Liu G, Peacock M, Eilam O, Dorulla G, Braunstein E, Johnston CC. Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int. 1997; 7: 564–569.
View Full Article (HTML) Get PDF (101K)